Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?

Neurology. 2021 May 18;96(20):927-928. doi: 10.1212/WNL.0000000000011928. Epub 2021 Apr 7.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Atrophy
  • Humans
  • Multiple Sclerosis*
  • Multiple Sclerosis, Relapsing-Remitting*
  • Retinal Degeneration*
  • Rituximab

Substances

  • Rituximab